The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli Lilly are both developing a new generation of obesity drugs. Eli Lilly and Novo Nordisk - the dominant players ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...